Celcuity adds ex-Incyte/Celgene CFO David Gryska to board; cites first FDA approval of REVTORPYK

Celcuity Inc.

Board expanded from eight to nine members; David W. Gryska appointed effective October 1, 2026, serving through the 2027 Annual Meeting.
Gryska was EVP and CFO of Incyte and SVP and CFO of Celgene, and earlier VP Finance/CFO at Scios and a partner at Ernst & Young.
He joins the Audit and Compensation Committees and is deemed independent under Nasdaq listing standards and SEC rules.
Pro-rated director pay: $70,000 annual cash retainer and $100,000 annual equity award; granted 893 RSUs vesting at the 2027 annual meeting or April 30, 2027.
CEO Brian Sullivan links the hire to the company's transition to commercial stage after the first FDA approval for REVTORPYK in advanced breast cancer and gedatolisib development.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.